Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways
Mahshid Deldar Abad Paskeh,Sepideh Mirzaei,Milad Ashrafizadeh,Ali Zarrabi,Gautam Sethi
DOI: https://doi.org/10.2147/JHC.S336858
2022-01-19
Journal of Hepatocellular Carcinoma
Abstract:Mahshid Deldar Abad Paskeh, 1, 2 Sepideh Mirzaei, 3 Milad Ashrafizadeh, 4, 5 Ali Zarrabi, 5, 6 Gautam Sethi 7, 8 1 Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; 2 Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; 3 Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran; 4 Faculty of Engineering and Natural Sciences, Sabanci University, Tuzla, Istanbul, Turkey; 5 Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, Istanbul, Turkey; 6 Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Sariyer, Istanbul, 34396, Turkey; 7 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; 8 Cancer Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore Correspondence: Sepideh Mirzaei Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran Email Gautam Sethi Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore Email Liver cancers cause a high rate of death worldwide and hepatocellular carcinoma (HCC) is considered as the most common primary liver cancer. HCC remains a challenging disease to treat. Wnt/β-catenin signaling pathway is considered a tumor-promoting factor in various cancers; hence, the present review focused on the role of Wnt signaling in HCC, and its association with progression and therapy response based on pre-clinical and clinical evidence. The nuclear translocation of β-catenin enhances expression level of genes such as c-Myc and MMPs in increasing cancer progression. The mutation of CTNNB1 gene encoding β-catenin and its overexpression can lead to HCC progression. β-catenin signaling enhances cancer stem cell features of HCC and promotes their growth rate. Furthermore, β-catenin prevents apoptosis in HCC cells and increases their migration via triggering EMT and upregulating MMP levels. It is suggested that β-catenin signaling participates in mediating drug resistance and immuno-resistance in HCC. Upstream mediators including ncRNAs can regulate β-catenin signaling in HCC. Anti-cancer agents inhibit β-catenin signaling and mediate its proteasomal degradation in HCC therapy. Furthermore, clinical studies have revealed the role of β-catenin and its gene mutation ( CTNBB1 ) in HCC progression. Based on these subjects, future experiments can focus on developing novel therapeutics targeting Wnt/β-catenin signaling in HCC therapy. Keywords: liver cancer, drug resistance, immunotherapy, Wnt signaling, non-coding RNAs Liver cancers are the fourth most common cancer worldwide. 1,2 Primary liver cancers are responsible for a major challenge in developed and developing countries and are correlated with clinical, economic, and psychological burden. 3 Hepatocellular carcinoma (HCC) is a troublesome problem for healthcare providers and comprises up to 85–90% of primary liver cancers. The risk factors for HCC are different based on region and country. For instance, chronic infection with hepatitis B virus (HBV), alcohol intake, and hepatitis C virus (HCV) lead to development of HCC. Risk factors are different in different countries, different genetic landscape and molecular subtype; and clinical emergence of HCC also varies based on region. 4–7 Antiviral treatment and HBV vaccination are considered as promising strategies to prevent HCC development. 8,9 Furthermore, advances in diagnosis and treatment of HCC have resulted in a significant decrease (20.3%) in mortality caused by HCC from 1990 to 2017. 10 There are some therapeutic strategies for HCC including liver resection, ablation and transplantation that show efficacy in early stages of this malignant tumor. Unfortunately, in spite of advances in diagnostic methods, HCC patients are often diagnosed in advanced stages, when therapy is almost impossible. 11,12 Therefore, novel imaging methods should be applied in HCC diagnosis. For instance, patients who have cirrhosis, are advised to be screened in terms of HCC development. 13 Besides, plasma, serum, and urine can be considered valuable sources for HCC diagnosis. 14 Due to diagnosis of HCC at advanced stages, risk of recurrence and metastatic nature of cancer cells, HCC patients have a 5-year survival rate -Abstract Truncated-
oncology